Global Contrast-Enhanced Mammography Market Strategic Research Report

Scope of the Report

The global Contrast-Enhanced Mammography market size is predicted to grow from US$ 295 million in 2025 to US$ 451 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.

Contrast-Enhanced Mammography (CEM) is a breast imaging technique that builds on standard digital mammography by administering intravenous iodinated contrast and acquiring dual-energy images (low- and high-energy) to reconstruct enhancement/“iodine-only” images. It provides both anatomic detail (similar to conventional mammography) and functional information related to vascularity and permeability, making contrast uptake more conspicuous in many cancers. CEM is particularly relevant for dense breasts, problem-solving in equivocal cases, scenarios where breast MRI is contraindicated or less accessible, and selected pathways such as preoperative evaluation and treatment follow-up. Its clinical and operational value depends on standardized contrast administration and timing, a robust dual-energy imaging chain, and workflow-integrated reading and reporting—so performance gains translate into reproducible, scalable practice. In 2025, global Contrast-Enhanced Mammography production reached approximately 1506 unit and price is about 200 K USD/Unit.The average gross profit margin of this product is 50%.

Sustained demand for earlier detection and higher-throughput breast imaging is pushing radiology departments to adopt solutions that improve sensitivity without disrupting established mammography infrastructure. CEM supports “bringing enhancement capability onto the mammography platform,” leveraging familiar equipment ecosystems and scalable protocols. For providers, CEM can serve as a complementary—or in selected indications, alternative—pathway to breast MRI, helping shorten diagnostic timelines, improve access, and align enhancement imaging with existing mammography workflows, QC frameworks, and staffing models. CEM combines contrast administration, radiation-based imaging, and workflow governance, meaning implementation barriers extend beyond hardware to patient screening (e.g., contrast reactions and renal considerations), timing control, emergency readiness, and cross-team coordination. Clinically, positioning CEM alongside MRI, ultrasound, and tomosynthesis requires clear boundaries and standardized interpretation training to avoid excessive false positives or unnecessary follow-ups. Without strong evidence loops and disciplined QC, hospitals may face uncertainty in defining CEM’s role and sustaining consistent utilization. Demand is shifting from single-test accuracy to pathway-level efficiency—linking CEM with tomosynthesis, targeted ultrasound, biopsy workflows, and preoperative decision-making to enable faster, more streamlined “test-to-decision” cycles. In practice, CEM is often expected to deliver the greatest incremental value in dense breasts, lesion stratification, and MRI-limited populations, with gradual expansion into higher-frequency follow-up and recurrence surveillance scenarios. Meanwhile, radiology leaders increasingly prioritize structured reporting, AI assistance, and cross-site consistency to operationalize quality at scale. The upstream value chain is anchored by “contrast agent & injection systems + dual-energy mammography platform + software/QA components.” Iodinated contrast media and injectors/consumables define administration stability and safety boundaries; dual-energy detectors, x-ray tubes, generators, and compression mechanics drive image consistency and reproducibility; and reconstruction/post-processing software (low-energy images, iodine/enhancement images, artifact suppression, dose management) determines readability and workflow efficiency. Competitive differentiation concentrates on balancing low dose with high contrast, user-friendly reconstruction and reading software, integration with RIS/PACS and structured reporting, and lifecycle QA and service delivery capabilities.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Contrast-Enhanced Mammography market?

What factors are driving Contrast-Enhanced Mammography market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Contrast-Enhanced Mammography market opportunities vary by end market size?

How does Contrast-Enhanced Mammography break out by Type, by Application?

This report presents a comprehensive overview of the global Contrast-Enhanced Mammography market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Dual-energy CEM
• Single-energy Enhanced

Segment by Clinical Purpose

• Screening
• Diagnostic Workup
• Pre-op Staging
• Other

Segment by Equipment Type

• Dedicated CEM Mammography
• Upgrade from Standard System
• Other

Segment by Application

• Hospital
• Physical Examination Center
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Contrast-Enhanced Mammography market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Physical Examination Center, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact